Carnosine

Last updated October 21, 2026. Approval line checked October 21, 2026. No compounding source date is assigned.

FDA status

Not approved

Not approved. This record is not an FDA-approved drug product. Approval, where it exists, is specific to a drug product, indication, and route.

FDA: Unapproved drugs

Evidence tier

Human Observational. The tier is the highest indexed study type. It is not a safety rating and it is not an FDA approval. Confidence score 3/5. 1,850 PubMed citations indexed.

Carnosine in the literature

Endogenous dipeptide (beta-alanyl-L-histidine) acting as antioxidant, pH buffer, and AGE inhibitor; chelates heavy metals and may inhibit amyloid beta aggregation.

What the literature studies

Anti-Aging & Neuroprotection

Evidence tier

Human Observational

Compounding record

Status not verified

Confidence
3/5

Regulatory record

Status not verified. No product-specific FDA primary source is recorded for this entry. FDA approval and compounding eligibility are not verified. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.

Regulatory source not verified; no checked date is assigned.

Broadly safe as oral supplement; variable bioavailability due to carnosinase degradation.

Questions

Educational only. Not medical advice. This page does not give doses or sourcing. See the medical and editorial disclaimer.